Drug Type Prophylactic vaccine, mRNA vaccine |
Synonyms Bemremeran, Coronavirus(SARS-CoV-2)RNA Vaccine, mRNA COVID-19 Vaccine (Daiichi Sankyo) + [7] |
Target |
Mechanism SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (02 Aug 2023), |
Regulation- |
Start Date09 Jan 2024 |
Sponsor / Collaborator- |
Start Date05 Jan 2024 |
Sponsor / Collaborator- |
Start Date19 May 2023 |
Sponsor / Collaborator- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 | JP | 02 Aug 2023 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |